Loading...
Loading...
ATXI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,708.0K |
| Operating I/L | -3,708.0K |
| Other Income/Expense | -641.0K |
| Interest Income | 49.0K |
| Pretax | -4,349.0K |
| Income Tax Expense | 9.0K |
| Net Income/Loss | -4,340.0K |
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the acute/intensive care hospital setting. The company's primary product candidate is intravenous Tramadol, a synthetic dual-acting opioid, currently in Phase III clinical trials for the treatment of post-operative acute pain.
